KalVista Pharmaceuticals, Inc. Income Statement
KALV / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 13 fiscal years. All figures from audited SEC 10-K filings.
Revenue has grown at a 42.0% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $50.0M | - | - | - | $12.7M | $12.7M | $2.1M | $8.4M | $1.5M | $2.1M | - | - |
| SG&A Expense | - | $116.3M | $54.3M | $30.6M | $26.4M | $16.6M | $13.0M | $2.7M | $8.9M | $11.2M | $1.6M | $3.4M | $1.4M |
| R&D Expense | $71.7M | $71.7M | $86.2M | $80.3M | $70.2M | $41.3M | $40.2M | $14.7M | $18.2M | $12.7M | $8.3M | $8.3M | $4.2M |
| Operating Income | -$188.0M | -$188.0M | -$140.4M | -$110.9M | -$96.6M | -$57.9M | -$40.5M | -$15.2M | -$18.7M | -$22.3M | -$8.1M | -$11.7M | -$5.2M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | $1.2M | $1.1M | $405.0K |
| Income Tax | $3.4M | $3.4M | $0 | $0 | $0 | $0 | -$124.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$183.4M | -$183.4M | -$126.6M | -$92.9M | -$82.3M | -$46.2M | -$29.1M | -$11.4M | -$15.8M | -$18.6M | -$11.4M | -$13.4M | -$5.7M |
| EPS (Basic) | -$3.44 | -$3.69 | -$3.44 | -$1.64 | - | -$2.42 | -$1.64 | - | - | - | - | - | - |
| EPS (Diluted) | -$3.44 | -$3.69 | -$3.44 | -$1.64 | -$1.38 | -$2.42 | -$1.64 | -$26.17 | - | - | - | - | - |
| Shares Outstanding | 42.5M | 49.7M | 36.8M | 24.4M | 17.8M | 17.8M | 17.3M | 9.7M | 10.3M | 4.6M | 263.4K | 612.5K | 423.1K |
| Operating Margin | - | - | - | - | - | -456.4% | -319.4% | -711.7% | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | -364.4% | -229.4% | -536.2% | -188.3% | - | - | - | - |